ReviewCurrent oncology reports2014
Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.
Review in Current oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Hereditary genetic testing and its application in the diagnosis, treatment, and prevention of breast cancer].Magyar onkologia · 2025Guideline
- A randomized experimental study to test the effects of discussing uncertainty during cancer genetic counseling: different strategies, different outcomes?European journal of human genetics : EJHG · 2021Trial
- Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.Journal of oncology practice · 2016Trial
- Landscape of germline genetic alterations among non-western young male patients with cancer. Findings from The Jordanian exploratory cancer genetics study.Frontiers in oncology · 2026Article
- Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers.Journal of genetic counseling · 2023Article
- Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer.Frontiers in genetics · 2023Article
- Review
- Germline mutations in Chinese ovarian cancer with or without breast cancer.Molecular genetics & genomic medicine · 2022Article
- "I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.Familial cancer · 2022Article
- Novel Diagnostic Value of Driver Gene Transcription Signatures to Characterise Clear Cell Renal Cell Carcinoma, ccRCC.Pathology oncology research : POR · 2022Article
- Hereditary variants of unknown significance in African American women with breast cancer.PloS one · 2022Article
- Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.Frontiers in oncology · 2022Article
- Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.Scientific reports · 2021Article
- Update on multi-gene panel testing and communication of genetic test results.The breast journal · 2020Article
- Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.Annals of surgical oncology · 2019Article
- Cancer Genetic Counseling and Testing in an Era of Rapid Change.Journal of genetic counseling · 2017Article
- Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.Journal of genetic counseling · 2017Article
- Issues Arising in Psychological Consultations to Help Parents Talk to Minor and Young Adult Children about their Cancer Genetic Test Result: a Guide to Providers.Journal of genetic counseling · 2017Article
- The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.Journal of genetic counseling · 2017Article
- Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation sequencing technology affords an unprecedented opportunity to analyze multiple breast cancer susceptibility genes simultaneously. With the incarnation of gene panels that combine testing for moderate- and high-penetrance genes, this technology has given birth to a paradigm shift in clinical genetic test offerings. A transformation in genetic counseling for cancer susceptibility will necessarily follow, with a shift from the traditional approach of single-gene testing to considerations of testing by multi-gene panels. At the same time, however, the opportunity to identify rare lesions underlying hereditary susceptibility has introduced new challenges. Available cancer risk estimates for genes included in panel tests may not be supported by evidence, and there is increased risk of identifying variants of uncertain significance (VUS). Management of individuals with rare pathogenic mutations may be unclear. We provide a summary of available evidence for breast cancer risks conferred by pathogenic mutations in genes commonly included in breast cancer susceptibility panels, as well as a review of limitations and counseling points.
Indexed as
Identifiers
24488544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.